Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
10:41am, Wednesday, 03'rd Sep 2025
Here is how Halozyme Therapeutics (HALO) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.
Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue?
10:15am, Wednesday, 03'rd Sep 2025
Halozyme Therapeutics (HALO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
New Strong Buy Stocks for September 3rd
07:26am, Wednesday, 03'rd Sep 2025
TDW, JRVR, HALO, SCSC and CSW have been added to the Zacks Rank #1 (Strong Buy) List on September 3, 2025.
Identify Superstar Stocks Like Halozyme with Money Flows
02:01pm, Friday, 29'th Aug 2025
Halozyme Therapeutics, Inc. (HALO) shares up 491% since first Big Money outlier inflow signal in March 2014.
Halozyme to Participate at Upcoming Investor Conferences
08:30am, Thursday, 28'th Aug 2025
SAN DIEGO , Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Inve
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
10:51am, Wednesday, 27'th Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 11'th Aug 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright
10:56am, Friday, 08'th Aug 2025
Halozyme Therapeutics, Inc. (HALO) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HALO's 50-day simple moving average crosse
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
10:40am, Friday, 08'th Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
01:01pm, Wednesday, 06'th Aug 2025
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.
Analysts Just Upgraded these Five Stocks
08:04am, Wednesday, 06'th Aug 2025
Bank of America reiterated its buy rating on Palantir with a price target of $180.
Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript
05:45am, Wednesday, 06'th Aug 2025
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Helen I. Torley - President, CEO & Director Nicole LaBrosse - Senior VP & CFO
Halozyme (HALO) Q2 EPS Jumps 69%
10:26pm, Tuesday, 05'th Aug 2025
Halozyme (HALO) Q2 EPS Jumps 69%
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
08:00pm, Tuesday, 05'th Aug 2025
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
07:06pm, Tuesday, 05'th Aug 2025
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $0.91 per share a year ago.
